Equities research analysts expect that Principia Biopharma Inc (NASDAQ:PRNB) will announce ($0.74) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Principia Biopharma’s earnings. The highest EPS estimate is ($0.54) and the lowest is ($0.96). Principia Biopharma posted earnings of $0.37 per share during the same quarter last year, which indicates a negative year over year growth rate of 300%. The business is expected to report its next quarterly earnings results on Tuesday, March 17th.
According to Zacks, analysts expect that Principia Biopharma will report full year earnings of ($2.01) per share for the current financial year, with EPS estimates ranging from ($2.16) to ($1.77). For the next year, analysts anticipate that the firm will post earnings of ($2.74) per share, with EPS estimates ranging from ($2.94) to ($2.31). Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Principia Biopharma.
Principia Biopharma (NASDAQ:PRNB) last released its earnings results on Tuesday, November 5th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.08). Principia Biopharma had a negative return on equity of 11.95% and a net margin of 11.88%.
A number of research firms have recently weighed in on PRNB. Stifel Nicolaus restated a “buy” rating on shares of Principia Biopharma in a research report on Tuesday, December 31st. ValuEngine downgraded Principia Biopharma from a “hold” rating to a “sell” rating in a research report on Tuesday, December 10th. Zacks Investment Research downgraded Principia Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, January 11th. Finally, HC Wainwright restated a “buy” rating and set a target price on shares of Principia Biopharma in a research report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Principia Biopharma has a consensus rating of “Hold” and an average price target of $58.25.
In related news, insider Dolca Thomas sold 495 shares of the company’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $60.00, for a total value of $29,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Simeon George acquired 357,142 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was bought at an average price of $31.12 per share, with a total value of $11,114,259.04. In the last quarter, insiders purchased 489,742 shares of company stock valued at $15,515,759 and sold 46,000 shares valued at $2,188,962. Corporate insiders own 28.98% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRNB. Bank of Montreal Can bought a new stake in Principia Biopharma in the second quarter valued at about $37,000. Public Employees Retirement System of Ohio acquired a new position in Principia Biopharma in the second quarter valued at about $59,000. Tower Research Capital LLC TRC grew its stake in Principia Biopharma by 1,786.7% in the second quarter. Tower Research Capital LLC TRC now owns 2,132 shares of the company’s stock valued at $71,000 after acquiring an additional 2,019 shares during the period. Metropolitan Life Insurance Co NY acquired a new position in Principia Biopharma in the third quarter valued at about $136,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Principia Biopharma in the second quarter valued at about $249,000. Institutional investors and hedge funds own 61.55% of the company’s stock.
Shares of PRNB stock traded up $1.77 on Friday, reaching $57.00. 4,491 shares of the stock were exchanged, compared to its average volume of 305,957. The stock has a market cap of $1.69 billion, a PE ratio of 98.95 and a beta of 1.37. Principia Biopharma has a one year low of $25.35 and a one year high of $61.07. The stock has a 50 day moving average price of $50.08 and a 200 day moving average price of $38.43.
Principia Biopharma Company Profile
Principia Biopharma Inc, a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura.
Read More: Correction
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.